187 related articles for article (PubMed ID: 23056559)
1. Increased oxidative damage in carriers of the germline TP53 p.R337H mutation.
Macedo GS; Lisbôa da Motta L; Giacomazzi J; Netto CB; Manfredini V; Vanzin CS; Vargas CR; Hainaut P; Klamt F; Ashton-Prolla P
PLoS One; 2012; 7(10):e47010. PubMed ID: 23056559
[TBL] [Abstract][Full Text] [Related]
2. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
3. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
4. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.
Giacomazzi J; Selistre S; Duarte J; Ribeiro JP; Vieira PJ; de Souza Macedo G; Rossi C; Czepielewski M; Netto CB; Hainaut P; Ashton-Prolla P
BMC Cancer; 2013 Apr; 13():187. PubMed ID: 23570263
[TBL] [Abstract][Full Text] [Related]
5. Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome.
Formiga MNDC; de Andrade KC; Kowalski LP; Achatz MI
JAMA Oncol; 2017 Oct; 3(10):1400-1402. PubMed ID: 28114597
[TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
[TBL] [Abstract][Full Text] [Related]
7. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
8. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
9. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
[TBL] [Abstract][Full Text] [Related]
10. The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers.
Fitarelli-Kiehl M; Giacomazzi J; Santos-Silva P; Graudenz MS; Palmero EI; Michelli RA; Achatz MI; de Toledo Osório CA; de Faria Ferraz VE; Picanço CG; Ashton-Prolla P
Fam Cancer; 2015 Jun; 14(2):333-6. PubMed ID: 25564201
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil.
Giacomazzi J; Graudenz MS; Osorio CA; Koehler-Santos P; Palmero EI; Zagonel-Oliveira M; Michelli RA; Scapulatempo Neto C; Fernandes GC; Achatz MI; Martel-Planche G; Soares FA; Caleffi M; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
PLoS One; 2014; 9(6):e99893. PubMed ID: 24936644
[TBL] [Abstract][Full Text] [Related]
12. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect.
Garritano S; Gemignani F; Palmero EI; Olivier M; Martel-Planche G; Le Calvez-Kelm F; Brugiéres L; Vargas FR; Brentani RR; Ashton-Prolla P; Landi S; Tavtigian SV; Hainaut P; Achatz MI
Hum Mutat; 2010 Feb; 31(2):143-50. PubMed ID: 19877175
[TBL] [Abstract][Full Text] [Related]
13. MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers.
Bandeira IC; Vieira IA; Andreis TF; Brussa Reis L; Macedo GS; Vianna FSL; Santos-Silva P; Palmero EI; Galvão HCR; Ramos CRN; Santiago KM; Achatz MI; da Costa AABA; Ashton-Prolla P
Cancer Genet; 2020 Jan; 240():54-58. PubMed ID: 31778928
[TBL] [Abstract][Full Text] [Related]
14. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil.
Assumpção JG; Seidinger AL; Mastellaro MJ; Ribeiro RC; Zambetti GP; Ganti R; Srivastava K; Shurtleff S; Pei D; Zeferino LC; Dufloth RM; Brandalise SR; Yunes JA
BMC Cancer; 2008 Dec; 8():357. PubMed ID: 19046423
[TBL] [Abstract][Full Text] [Related]
15. Identification of the
Sandoval RL; Masotti C; de Macedo MP; Ribeiro MFSA; Leite ACR; Meireles SI; Bovolin RM; Santini FC; Munhoz RR; Jardim DLF; Katz A; Camargo AA; Fernandes GDS; Achatz MI
JCO Glob Oncol; 2021 Jul; 7():1141-1150. PubMed ID: 34270331
[TBL] [Abstract][Full Text] [Related]
16. The Common Germline
Jeffers JR; Pinto EM; Rehg JE; Clay MR; Wang J; Neale G; Heath RJ; Lozano G; Lalli E; Figueiredo BC; Pappo AS; Rodriguez-Galindo C; Chen W; Pounds S; Ribeiro RC; Zambetti GP
Cancer Res; 2021 May; 81(9):2442-2456. PubMed ID: 33637564
[TBL] [Abstract][Full Text] [Related]
17. Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors.
Mastellaro MJ; Seidinger AL; Kang G; Abrahão R; Miranda ECM; Pounds SB; Cardinalli IA; Aguiar SS; Figueiredo BC; Rodriguez-Galindo C; Brandalise SR; Yunes JA; Barros-Filho AA; Ribeiro RC
Cancer; 2017 Aug; 123(16):3150-3158. PubMed ID: 28387921
[TBL] [Abstract][Full Text] [Related]
18. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation.
Figueiredo BC; Sandrini R; Zambetti GP; Pereira RM; Cheng C; Liu W; Lacerda L; Pianovski MA; Michalkiewicz E; Jenkins J; Rodriguez-Galindo C; Mastellaro MJ; Vianna S; Watanabe F; Sandrini F; Arram SB; Boffetta P; Ribeiro RC
J Med Genet; 2006 Jan; 43(1):91-6. PubMed ID: 16033918
[TBL] [Abstract][Full Text] [Related]
19. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
20. Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome.
Macedo GS; Araujo Vieira I; Brandalize AP; Giacomazzi J; Inez Palmero E; Volc S; Rodrigues Paixão-Côrtes V; Caleffi M; Silva Alves M; Achatz MI; Hainaut P; Ashton-Prolla P
Cancer Genet; 2016 Mar; 209(3):97-106. PubMed ID: 26823150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
